Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TACTI-002 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Phase II Study in Patients With Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC), or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic Squamous Head and Neck Cancer (HNSCC) Receiving the Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) in Combination With Pembrolizumab (PD-1 Antagonist)

Trial Profile

TACTI-002 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Phase II Study in Patients With Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC), or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic Squamous Head and Neck Cancer (HNSCC) Receiving the Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) in Combination With Pembrolizumab (PD-1 Antagonist)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs Eftilagimod alpha (Primary) ; Pembrolizumab (Primary)
  • Indications Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms TACTI-002
  • Sponsors Immutep Limited
  • Most Recent Events

    • 01 Nov 2018 According to an Immutep Limited media release, site start-up in all regions is advanced and the first site activation is expected shortly, potentially leading to the First Patient In (FPI), in early calendar 2019.
    • 01 Nov 2018 According to an Immutep Limited media release, site selection process is completed for this trial with upto 110 patients.Competent authority approval has already been received from the UKs Medicines & Healthcare products Regulatory Agency (MHRA), as well as a number of Ethics Committee approvals with the remaining approvals expected shortly.
    • 02 Oct 2018 According to an Immutep Limited media release, data will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top